# Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

> **NCT01468909** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 106 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **DRUG:** Pazopanib Hydrochloride
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01468909
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-12
- **Primary completion:** 2018-01-27
- **Final completion:** 2018-01-27
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468909, "Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01468909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*